Samsung Bioepis' European Whitepaper Proposes Solutions to Bridge Policy Gaps that Hinder Healthy Market Competition and Timely Access to Biosimilar Medicines

Samsung Bioepis Co., Ltd. today published a whitepaper titled ‘Solving the Biosimilar Void in Europe’ that proposes policy recommendations to fully recognize the value of biosimilars and ensure a more sustainable market in Europe.

and follow us on social media – LinkedIn, X.

____________________

1 IQVIA. The Impact of Biosimilar Competition in Europe. January 2025. Available at: https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2024.pdf

2 Medicines for Europe. The 2023 Market Review – European Biosimilar Medicine Markets – Policy Overview. September 2023. Available at: https://www.medicinesforeurope.com/wp-content/uploads/2023/09/Biosimilars-Market-Review-2023-final-06-09-2023.pdf

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20250710186470/en/